PMID- 34749016
OWN - NLM
STAT- MEDLINE
DCOM- 20221115
LR  - 20221222
IS  - 2320-2890 (Electronic)
IS  - 2319-4170 (Print)
IS  - 2319-4170 (Linking)
VI  - 45
IP  - 5
DP  - 2022 Oct
TI  - Stereotactic body radiotherapy plus cetuximab for previously irradiated 
      un-resectable head and neck cancer.
PG  - 838-846
LID - S2319-4170(21)00148-7 [pii]
LID - 10.1016/j.bj.2021.10.013 [doi]
AB  - BACKGROUND: The aim of the study was to explore the treatment outcomes and 
      prognostic factors for patients with previously irradiated but unresectable 
      recurrent head and neck squamous cell carcinoma (rHNSCC) treated by stereotactic 
      body radiotherapy (SBRT) plus cetuximab at a single institute in Taiwan. METHODS: 
      From February 2016 to March 2019, 74 patients with previously irradiated but 
      unresectable rHNSCC were treated with SBRT plus cetuximab. All patients received 
      irradiation to the gross tumor and/or nodal area with 40-50 Gy in five fractions, 
      with each fraction interval >/=2 days over a 2-week period by using the CyberKnife 
      M6 machine. An(18)F-fluorodeoxyglucose positron emission tomography-computed 
      tomography (PET-CT) scan was performed before treatment for treatment target 
      delineation (n = 74) and 2 months later for response evaluation (n = 60). The 
      median follow-up time was 9 months (range 1-36 months). RESULTS: The treatment 
      response rate was complete response: 25.0%, partial response: 41.7%, stable 
      disease: 11.7%, and progressive disease: 21.7% based on the criteria of the 
      Response Evaluation Criteria in Solid Tumors (n = 72) and complete metabolic 
      response: 21.7%, partial metabolic response: 51.7%, stable metabolic disease: 
      13.3%, and progressive metabolic disease: 13.3% based on PET-CT (n = 60), 
      respectively. The 1-/2-year overall survival (OS) and progression-free survival 
      (PFS) rates were 42.8%/22.0% and 40.5%/19.0%, respectively. In the logistic 
      regression model, a re-irradiation interval >12 months was observed to be the 
      only significant prognostic factor for a favorable treatment response. In the Cox 
      proportional hazards model, a re-irradiation interval >12 months and gross tumor 
      volume (GTV) <== 50 ml were favorable prognostic factors of OS and PFS. CONCLUSION: 
      SBRT plus cetuximab provides a promising salvage strategy for those patients with 
      previously irradiated but unresectable rHNSCC, especially those with a 
      re-irradiation interval >12 months or GTV <== 50 ml.
CI  - Copyright (c) 2021 Chang Gung University. Published by Elsevier B.V. All rights 
      reserved.
FAU - Huang, Tai-Lin
AU  - Huang TL
AD  - Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and 
      Chang Gung University College of Medicine, Kaohsiung, Taiwan.
FAU - Chuang, Hui-Ching
AU  - Chuang HC
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Kaohsiung, Taiwan; College of Medicine, 
      Chang Gung University, Taoyuan, Taiwan.
FAU - Tsai, Ming-Hsien
AU  - Tsai MH
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Kaohsiung, Taiwan.
FAU - Chien, Chih-Yen
AU  - Chien CY
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Kaohsiung, Taiwan; College of Medicine, 
      Chang Gung University, Taoyuan, Taiwan.
FAU - Su, Yan-Ye
AU  - Su YY
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Kaohsiung, Taiwan.
FAU - Lin, Yu-Tsai
AU  - Lin YT
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Kaohsiung, Taiwan.
FAU - Yang, Chao-Hui
AU  - Yang CH
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Kaohsiung, Taiwan.
FAU - Lai, Chi-Chih
AU  - Lai CC
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Kaohsiung, Taiwan.
FAU - Li, Shau-Hsuan
AU  - Li SH
AD  - Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and 
      Chang Gung University College of Medicine, Kaohsiung, Taiwan; College of 
      Medicine, Chang Gung University, Taoyuan, Taiwan.
FAU - Fang, Fu-Min
AU  - Fang FM
AD  - Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and 
      Chang Gung University College of Medicine, Kaohsiung, Taiwan; College of 
      Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address: 
      fang2569@cgmh.org.tw.
LA  - eng
PT  - Journal Article
DEP - 20211105
PL  - United States
TA  - Biomed J
JT  - Biomedical journal
JID - 101599820
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Humans
MH  - Cetuximab/therapeutic use
MH  - *Radiosurgery/adverse effects/methods
MH  - Positron Emission Tomography Computed Tomography
MH  - Neoplasm Recurrence, Local/surgery
MH  - *Head and Neck Neoplasms/drug therapy/radiotherapy/etiology
MH  - Squamous Cell Carcinoma of Head and Neck/radiotherapy
MH  - *Carcinoma
MH  - *Metabolic Diseases
PMC - PMC9661507
OTO - NOTNLM
OT  - Cetuximab
OT  - Gross tumor volume
OT  - Head and neck squamous cell carcinoma
OT  - PET-CT
OT  - Re-irradiation
OT  - Stereotactic body radiotherapy
EDAT- 2021/11/09 06:00
MHDA- 2022/11/16 06:00
PMCR- 2021/11/05
CRDT- 2021/11/08 20:16
PHST- 2021/02/17 00:00 [received]
PHST- 2021/10/28 00:00 [revised]
PHST- 2021/10/31 00:00 [accepted]
PHST- 2021/11/09 06:00 [pubmed]
PHST- 2022/11/16 06:00 [medline]
PHST- 2021/11/08 20:16 [entrez]
PHST- 2021/11/05 00:00 [pmc-release]
AID - S2319-4170(21)00148-7 [pii]
AID - 10.1016/j.bj.2021.10.013 [doi]
PST - ppublish
SO  - Biomed J. 2022 Oct;45(5):838-846. doi: 10.1016/j.bj.2021.10.013. Epub 2021 Nov 5.